Ryan P. Englander

ORCID: 0000-0003-3549-1455
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immunotherapy and Immune Responses
  • vaccines and immunoinformatics approaches
  • Monoclonal and Polyclonal Antibodies Research
  • T-cell and B-cell Immunology
  • Animal Genetics and Reproduction
  • RNA Interference and Gene Delivery
  • Immune Cell Function and Interaction
  • CRISPR and Genetic Engineering

University of Connecticut
2020-2021

UConn Health
2020

Identification of neoepitopes that are effective in cancer therapy is a major challenge creating vaccines. Here, using an entirely unbiased approach, we queried all possible mouse model and asked which those mediating tumor rejection and, independently, eliciting measurable CD8 response. This analysis uncovered large trove anticancer have strikingly different properties from conventional epitopes suggested algorithm to predict them. It also revealed our current methods prediction discard the...

10.1172/jci142823 article EN cc-by Journal of Clinical Investigation 2020-12-15

High-affinity MHC I-peptide interactions are considered essential for immunogenicity. However, some neo-epitopes with low affinity I have been reported to elicit CD8 T cell dependent tumor rejection in immunization-challenge studies. Here we show a mouse model that neo-epitope poorly binds is able enhance the immunogenicity of absence immunization. Fibrosarcoma cells naturally occurring mutation edited their wild type counterpart; then re-introduced order obtain line genetically identical...

10.1038/s41467-021-26646-5 article EN cc-by Nature Communications 2021-11-05

Abstract A high- affinity MHC I-peptide interaction is considered essential for immunogenicity. However, some neoepitopes with low affinities have been reported to elicit CD8-dependent tumor rejection in immunization-challenge studies. Here, we ask if a non-binder, tumor-rejection- mediating neoepitope influences the natural immunogenicity of vivo, absence artificial immunization. mutation MUT1 was edited its WT counterpart; then re-introduced into tumor, recapitulating MUT2. TILs from all...

10.21203/rs.3.rs-119173/v1 preprint EN cc-by Research Square (Research Square) 2020-12-11

Abstract Cancer neoepitopes are the only truly tumor-specific antigens and therefore, most suitable as cancer vaccines. Current methods to predict neoepitopes, based on studies of viral epitopes, emphasize high affinity MHC-peptide interactions. Increasing evidence in human murine models indicates that present neoepitope prediction mostly inaccurate predicting true MHC I-restricted neoepitopes. Here, a completely unbiased approach, all possible mouse tumor model were tested for their ability...

10.4049/jimmunol.204.supp.239.18 article EN The Journal of Immunology 2020-05-01
Coming Soon ...